You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
RED BLOOD CELL ANTIBODY TITER |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2993 Geisinger Epic ID: 26821 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Whole blood. | |
Preferred collection container: |
||
Specimen required: |
6 mL whole blood | |
Special notes: |
Specimen must be labeled with patient's first and last name, medical record number or some unique other identifier (e.g.,billing number, NOT date of birth). Date of collection and phlebotomist identification (full name or tech ID) must be available. Positive patient identification must be assured. | |
Patient preparation: |
None. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Do not centrifuge or aliquot. | |
Transport temperature: |
Room temperature. | |
Specimen stability: |
Specimen must be less than 3 days old for testing. | |
Rejection criteria: |
Tube containing gel separator. Incomplete label ID (see specimen collection notes). | |
TEST DETAILS |
||
Reference interval: |
N/A. | |
Critical values/courtesy alerts: |
Critical titer in OB patients is 16, except for Anti-Kell, which is critical whenever present. | |
CPT code(s): |
86886 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Antibody titer. | |
Methodology: |
RBC Agglutination |
|
Synonyms: |
ATITER, Antibody titration
|
|
Clinical significance: |
During pregnancy antibody titration is performed to identify women with significant levels of antibodies that may lead to hemolytic disease of the fetus and newborn. A baseline is established for comparison with titers performed at a recommended every-4-week-interval during pregnancy. Anti-Kell titers are not performed since Kell titer does not correlate with fetal status. | |
Doctoral Director(s:) |
Gustaaf de Ridder MD, PhD | |
| Review Date: | 11/18/2020 | |